Your browser doesn't support javascript.
loading
Repeated Leftover Serosurvey of SARS-CoV-2 IgG Antibodies in Greece, May to August 2020.
Bogogiannidou, Zacharoula; Speletas, Matthaios; Vontas, Alexandros; Nikoulis, Dimitrios J; Dadouli, Katerina; Kyritsi, Maria A; Mouchtouri, Varvara A; Mina, Paraskevi; Anagnostopoulos, Lemonia; Koureas, Michalis; Karavasilis, Vasileios; Nikou, Olga; Pinaka, Ourania; Thomaidis, Pavlos C; Kadoglou, Kornilia; Bedevis, Konstantinos; Spyrou, Natalia; Eleftheriou, Alexandros A; Papaevangelou, Vassiliki; Gikas, Achilleas; Vatopoulos, Alkiviadis; Ntzani, Evangelia E; Prezerakos, Panagiotis; Tsiodras, Sotirios; Hadjichristodoulou, Christos.
  • Bogogiannidou Z; Laboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, Greece.
  • Speletas M; Department of Immunology and Histocompatibility, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece.
  • Vontas A; Laboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, Greece.
  • Nikoulis DJ; Laboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, Greece.
  • Dadouli K; Laboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, Greece.
  • Kyritsi MA; Laboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, Greece.
  • Mouchtouri VA; Laboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, Greece.
  • Mina P; Laboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, Greece.
  • Anagnostopoulos L; Laboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, Greece.
  • Koureas M; Laboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, Greece.
  • Karavasilis V; Laboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, Greece.
  • Nikou O; Laboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, Greece.
  • Pinaka O; Laboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, Greece.
  • Thomaidis PC; Microbiological Laboratory "Thomaidis", 20131 Korinthos, Greece.
  • Kadoglou K; Biochemistry Laboratory, General Hospital of Kalamata, 24150 Kalamata, Greece.
  • Bedevis K; Microbiological Laboratory "Bedevis Konstantinos", 22100 Tripoli, Greece.
  • Spyrou N; Microbiological Laboratory "Bioiatriki", 11524 Athens, Greece.
  • Eleftheriou AA; Department of Hygiene and Epidemiology, University of Ioannina Faculty of Medicine, 45110 Ioannina, Greece.
  • Papaevangelou V; Third Department of Paediatrics, School of Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.
  • Gikas A; Internal Medicine Department, Infectious Diseases Unit, University Hospital of Heraklion, School of Medicine, University of Crete, 71500 Heraklion, Greece.
  • Vatopoulos A; Department of Public Health Policy, School of Public Health, University of West Attica, 11521 Athens, Greece.
  • Ntzani EE; Department of Hygiene and Epidemiology, University of Ioannina Faculty of Medicine, 45110 Ioannina, Greece.
  • Prezerakos P; Center for Evidence Synthesis in Health, Department of Health Services, Policy and Practice, School of Public Health, Brown University, Providence, RI 02903, USA.
  • Tsiodras S; Institute of Biosciences, University Research Center of loannina, 45110 Ioannina, Greece.
  • Hadjichristodoulou C; Department of Nursing, University of Peloponnese, 22100 Tripoli, Greece.
Vaccines (Basel) ; 9(5)2021 May 13.
Article en En | MEDLINE | ID: mdl-34068100
A serosurvey of IgG antibodies against SARS-CoV-2 was conducted in Greece between May and August 2020. It was designed as a cross-sectional survey and was repeated at monthly intervals. The leftover sampling methodology was used and a geographically stratified sampling plan was applied. Of 20,110 serum samples collected, 89 (0.44%) were found to be positive for anti-SARS-CoV-2 antibodies, with higher seroprevalence (0.35%) observed in May 2020. The highest seroprevalence was primarily observed in the "30-49" year age group. Females presented higher seroprevalence compared to males in May 2020 (females: 0.58% VS males: 0.10%). This difference reversed during the study period and males presented a higher proportion in August 2020 (females: 0.12% VS males: 0.58%). Differences in the rate of seropositivity between urban areas and the rest of the country were also observed during the study period. The four-month infection fatality rate (IFR) was estimated to be 0.47%, while the respective case fatality rate (CFR) was at 1.89%. Our findings confirm low seroprevalence of COVID-19 in Greece during the study period. The young adults are presented as the most affected age group. The loss of the cumulative effect of seropositivity in a proportion of previous SARS-CoV-2 infections was indicated.
Palabras clave